This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
If You Invested $1000 in Novo Nordisk 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Top Stock Reports for Visa, Novo Nordisk & Medtronic
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including Visa Inc. (V), Novo Nordisk A/S (NVO) and Medtronic plc (MDT).
Novo Nordisk (NVO) Rides on Ozempic & Wegovy Amid Rivalry
by Zacks Equity Research
Novo Nordisk (NVO) continues to witness increasing demand for its diabetes and obesity care products like Ozempic, Wegovy and Rybelsus amid rising competition from other pharma bigwigs.
3 Reasons Why Novo Nordisk (NVO) Is a Great Growth Stock
by Zacks Equity Research
Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Pharma Stock Roundup: LLY, BAYRY Post Q2 Results, NVO's Wegovy Cuts Heart Attack Risk
by Kinjel Shah
Eli Lilly (LLY), Bayer (BAYRY) and Novo Nordisk (NVO) announce second-quarter results.
Novo Nordisk (NVO) Q2 Earnings and Sales Miss, 2023 View Up
by Zacks Equity Research
Novo Nordisk (NVO) reports weaker-than-expected second-quarter 2023 results, missing both earnings and sales estimates. Management, however, raises 2023 guidance.
Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Iovance (IOVA) reports mixed second-quarter results as earnings beat estimates but sales miss the mark.
Novavax (NVAX) Q2 Earnings Beat, Stock Down 4% on '23 Sales Cut
by Zacks Equity Research
Novavax (NVAX) reports better-than-expected Q2 earnings results, as earnings and revenues beat estimates. Shares drop due to lowered 2023 product sales guidance.
Eli Lilly (LLY) Q2 Earnings Beat, Mounjaro Powers Sales Growth
by Zacks Equity Research
Eli Lilly (LLY) beats second-quarter estimates for earnings and sales. It raises its financial guidance for 2023.
Perrigo (PRGO) Beats on Q2 Earnings & Sales, Reiterates '23 View
by Zacks Equity Research
Perrigo (PRGO) reports encouraging second-quarter 2023 results. Management reaffirms the financial guidance for 2023.
Bayer (BAYRY) Q2 Earnings Miss Estimates, '23 Outlook Lowered
by Zacks Equity Research
Bayer (BAYRY) misses earnings and sales estimates in the second quarter of 2023 due to lower volumes and decreased prices for glyphosate-based products. Management lowers its guidance.
Novo Nordisk (NVO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Novo Nordisk's (NVO) Diabetes and Obesity Care products are expected to have boosted sales in the second quarter of 2023 amid severe competition and pricing pressure in the United States.
Prothena (PRTA) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Prothena (PRTA) reports a wider-than-expected loss in the second quarter. The company makes considerable pipeline progress and updates 2023 bottom-line guidance.
Buy These 3 Top-Ranked Stocks for Dividend Growth
by Derek Lewis
Companies that pay dividends are often well-established, as they generally are no longer experiencing supercharged growth and opt to share profits with shareholders.
Is a Surprise Coming for Novo Nordisk (NVO) This Earnings Season?
by Zacks Equity Research
Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Moderna (MRNA) to Report Q2 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.
Amgen (AMGN) to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Gilead (GILD) Gears Up to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its second-quarter 2023 results.
Vertex (VRTX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex's (VRTX) Q2 earnings call, investors focus will likely be on the sales performance of its cystic fibrosis medicines and development updates of its non-CF pipeline.
Merck (MRK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q2 earnings.
Novo Nordisk (NVO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Novo Nordisk (NVO) closed at $162.31, marking a +0.15% move from the previous day.
Bristol-Myers (BMY) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q2 results.
Pfizer (PFE) to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q2.
Here's What to Expect From Acadia Healthcare's (ACHC) Q2 Earnings
by Zacks Equity Research
Acadia Healthcare's (ACHC) Q2 results are likely to reflect increased patient volumes across its U.S. operations, partly offset by a higher expense base.
Novo Nordisk (NVO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Novo Nordisk (NVO) closed at $160.25, marking a -0.43% move from the previous day.